Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/09/2025 10:29 PDT] Editas Medicine, Inc. (NASDAQ:EDIT), Up By 100% ($2.54) From $2.54 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [07/09/2025 10:29 PDT] Editas Medicine, Inc. (NASDAQ:EDIT), Up By 100% ($2.57) From $2.57 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [07/08/2025 07:18 PDT] EDIT Expected to Trade Up After Bullish Patterns Develop
• [07/07/2025 09:45 PDT] EDIT Expected to Trade Up After Bullish Patterns Develop
• [06/25/2025 07:10 PDT] EDIT Expected to Trade Down After Bearish Patterns Develop
• [06/17/2025 10:29 PDT] Editas Medicine, Inc. (NASDAQ:EDIT), Up By 100% ($1.83) From $1.83 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/05/2025 07:18 PDT] EDIT, Expected to Trade Lower After Bearish Insider Trading
• [05/30/2025 06:59 PDT] EDIT Expected to Trade Up After Bullish Patterns Develop